These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1088 related items for PubMed ID: 26996778

  • 21. Amyloid imaging with (11)C-PIB PET/CT and glucose metabolism with (18)F-FDG PET/CT in a study on cognitive impairment in the clinical setting.
    Banzo I, Jiménez-Bonilla J, Ortega-Nava F, Quirce R, Martínez-Rodríguez I, de Arcocha-Torres M, Rodríguez E, Vázquez JL, Sánchez PJ, Martínez-Amador N, Ibañez-Bravo S, Carril JM.
    Nucl Med Commun; 2014 Mar; 35(3):238-44. PubMed ID: 24240196
    [Abstract] [Full Text] [Related]

  • 22. Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease.
    Leuzy A, Cicognola C, Chiotis K, Saint-Aubert L, Lemoine L, Andreasen N, Zetterberg H, Ye K, Blennow K, Höglund K, Nordberg A.
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1152-1163. PubMed ID: 30610252
    [Abstract] [Full Text] [Related]

  • 23. [18F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease.
    Chiotis K, Savitcheva I, Poulakis K, Saint-Aubert L, Wall A, Antoni G, Nordberg A.
    Mol Psychiatry; 2021 Oct; 26(10):5875-5887. PubMed ID: 32616831
    [Abstract] [Full Text] [Related]

  • 24. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease.
    Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Doré V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N.
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):816-26. PubMed ID: 24514874
    [Abstract] [Full Text] [Related]

  • 25. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Schöll M, Chiotis K, Thordardottir S, Graff C, Wall A, Långström B, Nordberg A.
    Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
    [Abstract] [Full Text] [Related]

  • 26. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T, Wutz C, Alexopoulos P, Drzezga A, Förster S, Förstl H, Goldhardt O, Ortner M, Sorg C, Kurz A.
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [Abstract] [Full Text] [Related]

  • 27. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, McDade E, Aizenstein HJ, Klunk WE, Mathis CA.
    Neuroimage Clin; 2015 Feb; 9():592-8. PubMed ID: 26640770
    [Abstract] [Full Text] [Related]

  • 28. Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease.
    Colato E, Chiotis K, Ferreira D, Mazrina MS, Lemoine L, Mohanty R, Westman E, Nordberg A, Rodriguez-Vieitez E, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2021 Feb; 84(1):103-117. PubMed ID: 34511502
    [Abstract] [Full Text] [Related]

  • 29. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L, Chiotis K, Alongi P, Almkvist O, Wall A, Cerami C, Bettinardi V, Gianolli L, Nordberg A, Perani D.
    J Alzheimers Dis; 2017 Feb; 59(2):603-614. PubMed ID: 28671117
    [Abstract] [Full Text] [Related]

  • 30. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ, Devous MD, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA, 18F-AV-1451-A05 investigators.
    Brain; 2017 Mar 01; 140(3):748-763. PubMed ID: 28077397
    [Abstract] [Full Text] [Related]

  • 31. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.
    Forsberg A, Almkvist O, Engler H, Wall A, Långström B, Nordberg A.
    Curr Alzheimer Res; 2010 Feb 01; 7(1):56-66. PubMed ID: 20205671
    [Abstract] [Full Text] [Related]

  • 32. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST.
    Brain; 2008 Jun 01; 131(Pt 6):1630-45. PubMed ID: 18339640
    [Abstract] [Full Text] [Related]

  • 33. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S, AIBL Research Group.
    J Alzheimers Dis; 2015 Jun 01; 48(1):175-87. PubMed ID: 26401938
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
    Carneiro CG, Faria DP, Coutinho AM, Ono CR, Duran FLS, da Costa NA, Garcez AT, da Silveira PS, Forlenza OV, Brucki SMD, Nitrini R, Busatto G, Buchpiguel CA.
    Braz J Psychiatry; 2022 Aug 15; 44(5):495-506. PubMed ID: 36420910
    [Abstract] [Full Text] [Related]

  • 35. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S, Wakebe D.
    J Alzheimers Dis; 2017 Aug 15; 57(3):765-773. PubMed ID: 28304292
    [Abstract] [Full Text] [Related]

  • 36. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
    Bunai T, Kakimoto A, Yoshikawa E, Terada T, Ouchi Y.
    J Alzheimers Dis; 2019 Aug 15; 69(2):529-538. PubMed ID: 31104023
    [Abstract] [Full Text] [Related]

  • 37. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R, Zwan MD, Tolboom N, van Assema DM, Adriaanse SF, Kloet RW, Boellaard R, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BN.
    Brain; 2012 Jul 15; 135(Pt 7):2115-25. PubMed ID: 22556189
    [Abstract] [Full Text] [Related]

  • 38. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
    Soleimani-Meigooni DN, Iaccarino L, La Joie R, Baker S, Bourakova V, Boxer AL, Edwards L, Eser R, Gorno-Tempini ML, Jagust WJ, Janabi M, Kramer JH, Lesman-Segev OH, Mellinger T, Miller BL, Pham J, Rosen HJ, Spina S, Seeley WW, Strom A, Grinberg LT, Rabinovici GD.
    Brain; 2020 Dec 05; 143(11):3477-3494. PubMed ID: 33141172
    [Abstract] [Full Text] [Related]

  • 39. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.
    Ito H, Shinotoh H, Shimada H, Miyoshi M, Yanai K, Okamura N, Takano H, Takahashi H, Arakawa R, Kodaka F, Ono M, Eguchi Y, Higuchi M, Fukumura T, Suhara T.
    Eur J Nucl Med Mol Imaging; 2014 Apr 05; 41(4):745-54. PubMed ID: 24233004
    [Abstract] [Full Text] [Related]

  • 40. Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients.
    Choo IL, Carter SF, Schöll ML, Nordberg A.
    Eur J Nucl Med Mol Imaging; 2014 Nov 05; 41(11):2120-6. PubMed ID: 25077930
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 55.